# Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)

> **NCT06970106** · PHASE1,PHASE2 · RECRUITING · sponsor: **PYC Therapeutics** · enrollment: 18 (estimated)

## Conditions studied

- OPA1 Gene Mutation
- Autosomal Dominant Optic Atrophy
- Hereditary Optic Atrophies
- Kjer Optic Atrophy

## Interventions

- **DRUG:** PYC-001

## Key facts

- **NCT ID:** NCT06970106
- **Lead sponsor:** PYC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06970106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06970106, "Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06970106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*